Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 12, 2018 - Issue 10
Submit an article Journal homepage
91
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials

Hani OweiraDepartment of surgery, Gastrointestinal Tumor Zentrum, Zürich, SwitzerlandView further author information
,
Anwar GiryesDepartment of surgery, Gastrointestinal Tumor Zentrum, Zürich, SwitzerlandView further author information
,
Meinrad MannhartDepartment of Oncology, Center of Zug, Zug, SwitzerlandView further author information
,
Michael DeckerZentrum für Integrative Onkologie, Zurich, SwitzerlandView further author information
&
Omar Abdel-RahmanClinical Oncology department, faculty of medicine, Ain shams university, Cairo, Egypt;Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, CanadaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5117-2502View further author information
ORCID Icon
Pages 1069-1074 | Received 13 May 2018, Accepted 09 Aug 2018, Published online: 20 Aug 2018

References

  • GLOBOCAN database. [cited 2016 Nov 27]. Available from: globocan.iarc.fr
  • Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–72.
  • Byun JH, Ahn JB, Kim SY, et al. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Korean J Intern Med. 2017.
  • Karim S, Brennan K, Nanji S, et al. Association between prognosis and tumor laterality in early-stage colon cancer. JAMA Oncol. 2017;3:1386–1392.
  • Abdel-Rahman O. Challenging a dogma: five-year survival does not equal cure in all colorectal cancer patients. Expert Rev Anticancer Ther. 2018 Feb;18(2):187–192.
  • Bos ACRK, van Erning FN, van Gestel YRBM, et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer. 2015;51:2553–2561.
  • Gresham G, Cheung WY, Speers C, et al. Time to adjuvant chemotherapy and survival outcomes among patients with stage 2 to 3 rectal cancer treated with preoperative chemoradiation. Clin Colorectal Cancer. 2015;14:41–45.
  • Project data sphere website. [cited 2018 Jul 7]. Available from: https://www.projectdatasphere.org/projectdatasphere/html/home
  • Renfro LA, Loupakis F, Adams RA, et al. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. J Clin Oncol. 2016;34:144–150.
  • Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007;11:1–128, iii-iv.
  • Abdel-Rahman O. Revisiting Dukes’ paradigm; some node positive colon cancer patients have better prognosis than some node negative patients. Clin Transl Oncol. 2018 Jun;20(6):794–800.
  • Bauer KM, Hummon AB, Buechler S. Right-side and left-side colon cancer follow different pathways to relapse. Mol Carcinog. 2012;51:411–421.
  • Abdel-Rahman O. Challenging a dogma: five-year survival does not equal cure in all colorectal cancer patients. Expert Rev Anticancer Ther. 2018;18:187–192.
  • Ashktorab H, Smoot DT, Carethers JM, et al. High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res. 2003;9:1112–1117.
  • Ashktorab H, Smoot DT, Farzanmehr H, et al. Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer. 2005;116:914–919.
  • Benson AB 3rd, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014;12:1028–1059.
  • Jo WS, Carethers JM. Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark. 2006;2:51–60.
  • Kim MS, Chung M, Ahn JB, et al. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis. J Surg Oncol. 2014;110:214–221.
  • Wang Z, Liang L, Yu Y, et al. Primary tumour resection could improve the survival of unresectable metastatic colorectal cancer patients receiving bevacizumab-containing chemotherapy. Cell Physiol Biochem. 2016;39:1239–1246.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.